ArticleJournal of neuro-oncology2009
Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases.
Article in Journal of neuro-oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 52 citations in OpenAlex.
- Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma.PloS one · 2013Trial
- Long Term Survival in Patients Suffering from Glio-blastoma Multiforme: A Single-Center Observational Cohort Study.Diagnostics (Basel, Switzerland) · 2019Article
- Radiological imaging features of glioblastoma with oligodendroglioma component: a comparison with conventional glioblastoma.Acta radiologica open · 2016Article
- [Principles and applications of susceptibility weighted imaging].Der Radiologe · 2016Review
- Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.Acta neuropathologica communications · 2016Article
- Adult intraventricular astroblastoma.Singapore medical journal · 2016Article
- Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging.Neuroradiology · 2015Article
- Genetic analysis of a case of glioblastoma with oligodendroglial component arising during the progression of diffuse astrocytoma.Pathology oncology research : POR · 2015Article
- Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients.European journal of nuclear medicine and molecular imaging · 2015Article
- Synchronous multicentric glioblastoma with PNET and O subtypes: Possible pathogenesis.Surgical neurology international · 2014Article
- Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.Neuro-oncology · 2013Article
- Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics.Brain pathology (Zurich, Switzerland) · 2013Article
- Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age.Journal of neuro-oncology · 2013Article
- Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.AJNR. American journal of neuroradiology · 2012Article
- Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies.Neuropathology and applied neurobiology · 2012Review
- Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome.Neuro-oncology · 2012Article
- Forced Abstinence from Cocaine Self-Administration is Associated with DNA Methylation Changes in Myelin Genes in the Corpus Callosum: a Preliminary Study.Frontiers in psychiatry · 2012Article
- Article
- Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays.The Journal of molecular diagnostics : JMD · 2011Article
- Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma.Neuro-oncology · 2011Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Not all Glioblastoma multiforme (GBM, grade IV WHO) manifest the same clinical course. Different prognostic classes may arise from different morphologic and genetic profiles. The observation of oligodendroglial foci within GBM samples and their correlation with genetic alterations may predict a better prognosis. 450 patients affected by histologically proven supratentorial cerebral GBM were treated at our institutions from January 2000 to December 2006: all patients received at least subtotal surgical removal, followed by the same standard radio-chemotherapy adjuvant treatment. In a subgroup of 36 patients (8.0%) an oligodendroglial component was observed. Molecular assessment of these cases was performed and LOH for 1p, 19q and 10q, EGFR amplification and TP53 gene expression was determined. Median age of this subgroup was 52.1 years (range: 29-78 years) vs 62.4 years in the entire GBM population. Chromosome analysis resulted as follows: LOH 1p and/or 19q in 27 cases (75.0%), LOH of 10q in 21 cases (58.1%), EGFR amplification in 14 cases (39%) and TP53 mutation in eight patients (22.2%). OS was of 20.9 months while it was 13.6 months in the entire GBM population. Progression free survival (PFS) was 10.3 months and 7.6 months the entire group. Two-year survival was of 55%. The presence of an oligodendroglial component in GBM appears to be an important prognostic factor to which better prognosis can be related. LOH 1p and 19q was significantly associated with GBM with oligodendroglial component.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.